We have compiled an updated lengthy 2009 American Society of Clinical Oncology, or ASCO, document showing many company cancer data presentations slated to start this weekend. This is broken down in drug…
These are the top pre-market analyst downgrades and negative research calls we have seen from Wall Street early this Friday morning: Akamai Tech (AKAM) Cut to Hold at Citigroup. Bristol-Myers Squibb (BMY)…
It has been no secret that the market for initial public offerings has been one of the biggest ghost towns in the financial markets. The secondary markets and the bond markets are…
If you can believe it, there is an initial public offering on deck this week. Bristol-Myers Squibb Co. (NYSE: BMY) is set to partially spin off Mead Johnson Nutrition (NYSE: MJN). It…
Douglas A. McIntyre We haven’t been covering Jim Cramer as much for many different reasons, but we still pay attention when he comes out with stock picks because it can still affect at least the…
There may be some speculation that drug giant Pfizer Inc. (NYSE: PFE) is looking at expansion through acquisitions. The FT reported that the world’s largest pharmaceutical company is willing to acquire a…
People who get to the end of 2008 and are still at work can be thankful. The unemployment rate will probably be over 7%. That does not count the people no longer…
According to Reuters, the Fed may need to use a trillion dollars to halt the economy from moving into a period of deflation. Reuters reports that OPEC will make the largest production…
There are few positive calls this morning from Wall Street analysts, but these are the ones we have caught this morning: Alcatel-Lucent (ALU) Raised to Sector Perform at RBC. ASUR (ASR) Raised…
These are some of the top analyst upgrades we have seen this Friday morning: Abercrombie & Fitch (ANF) Raised to Hold at Jefferies. Bristol-Myers Squibb (BMY) Started as Buy at Goldman Sachs.…
Analysts assume third quarter earnings for the companies in the S&P 500 will be bad. But, looking at the number which is the average of all firms in the index is misleading.…
Carl Icahn appears to have won a blue ribbon for ImClone Systems (NASDAQ: IMCL) shareholders. The biotech stock is trading up on a very weak trading day after what many had deemed…
ImClone Systems Inc. (NASDAQ: IMCL) is among the biotech bonanza merger candidates with one deal on the table and perhaps an unofficial deal waiting in the wings. Bristol-Myers Squibb Co. (NYSE: BMY)…
Douglas A. McIntyre According to Reuters, Wilbur Ross say the bailout package does not address the core of problem which is mortgage payments. Reuters writes that the National Retail Federation says that this will be…
There is some very hopeful data out there this morning on cancer survival. Bristol-Myers Squibb Co. (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) have released updated survival data from three Phase II…